Skip to main navigation Skip to search Skip to main content

Solitary sclerosis: Progressive myelopathy from solitary demyelinating lesion

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To present a case series of patients with progressive myelopathy in the setting of a solitary demyelinating lesion. Methods: We describe 7 patients evaluated over a 6-year period. All had progressive motor impairment attributable to an MRI lesion compatible with a demyelinating plaque in the brainstem or upper cervical spinal cord. At the time of evaluation, none met the International Panel imaging criteria for dissemination in space, and none described clinical symptoms consistent with relapses affecting other portions of the CNS. Results: Lesions identified were in the ventral cervicomedullary junction in 4 patients, the ventral spinal cord in 2 patients, and the pons in 1 patient. Median age at onset was 43 years (range 33-51 years). Median follow-up interval was 3 years (range 2-27 years). Six patients reached an Expanded Disability Status Scale (EDSS) score of 6.0 or worse. Median time to EDSS score of 6.0 was 7.5 years (range 1.5-26 years). Four had CSF findings characteristic of multiple sclerosis (MS). None had CSF, imaging, or serologic evidence of an alternative etiology of progressive myelopathy. In 3 patients, serial MRI scans of the brain and spinal cord demonstrated no accumulation of lesions. Postmortem examination of a fourth patient demonstrated an isolated pontine demyelinating lesion. Conclusions: Solitary demyelinating lesions may produce a progressive myelopathy similar to primary progressive MS. Demyelinating disease should be in the differential diagnosis of progressive myelopathy despite absence of dissemination in space.

Original languageEnglish (US)
Pages (from-to)540-544
Number of pages5
JournalNeurology
Volume78
Issue number8
DOIs
StatePublished - Feb 21 2012

Bibliographical note

Funding Information:
Dr. Schmalstieg receives research support from the National Multiple Sclerosis Society. Dr. Keegan serves as a Section Editor for Neurology and as Chief Editor for eMedicine and has served as a consultant for Novartis, Bionest Parners, and the FDA. Dr. Weinshenker serves on data safety monitoring boards for Novartis and Biogen Idec; serves on the editorial boards of the Canadian Journal of Neurological Sciences , the Turkish Journal of Neurology , and Multiple Sclerosis ; has received research support from Genzyme Corporation and the Guthy-Jackson Charitable Foundation; and receives license royalties from RSR Ltd. for a patent re: Aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica.

Fingerprint

Dive into the research topics of 'Solitary sclerosis: Progressive myelopathy from solitary demyelinating lesion'. Together they form a unique fingerprint.

Cite this